{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-080630","form_type":"8-K","ticker":"ERAS","cik":"0001761918","company_name":"Erasca, Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.439926+00:00","generated_at":"2026-06-04T06:18:33.813358+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Erasca raises $45M in oversubscribed private placement at $2.06/share","bullets":["Sold 21,844,660 shares at $2.06 each to institutional investors; gross proceeds ~$45M.","Private placement led by new and existing healthcare investors; BofA Securities acted as placement agent.","Expected closing on or about April 2, 2024, subject to customary closing conditions.","Proceeds to fund R&D, working capital; combined cash expected to fund operations into H2 2026.","Press release highlights naporafenib plus trametinib data showing 13-14 months median OS in NRAS-mutant melanoma."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-080630","json":"https://secwatch.observer/filing/0001193125-24-080630.json","markdown":"https://secwatch.observer/filing/0001193125-24-080630.md","text":"https://secwatch.observer/filing/0001193125-24-080630.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761918/000119312524080630/0001193125-24-080630-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761918/000119312524080630/d808774d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:18:33.813358+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5a94a975a01778796dd010df9de7752bda720670","claim":"Erasca, Inc. entered into Purchase Agreement with the purchasers named therein (the \"Purchasers\") valued at approximately $45 million (effective 2024-03-27).","evidence_excerpt":"On March 27, 2024, Erasca, Inc. (the “Company”) entered into a stock purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the private placement (the “Private Placement”) of 21,844,660 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a price of $2.06 per Share. The aggregate gross proceeds for the Private Placement are expected to be approximately $45 million, before deducting offering fees and expenses.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761918/000119312524080630/0001193125-24-080630-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the purchasers named therein (the \"Purchasers\")"},{"label":"Value","value":"approximately $45 million"},{"label":"Effective","value":"2024-03-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}